2022 | Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study | Ahn, Myung J; Kim, Hye R; CHIH-HSIN YANG ; Han, Ji-Yu; Li, Jacky Yu-Chung; Hochmair, Maximilian J; Chang, Gee-Chen; Delmonte, Angelo; Lee, Ki H; Campelo, Rosario G; Gridelli, Cesare; Spira, Alexander I; Califano, Raffaele; Griesinger, Frank; Ghosh, Sharmistha; Felip, Enriqueta; Kim, Dong-Wan; Liu, Yuyin; Zhang, Pingkuan; Popat, Sanjay; Camidge, D Ross | Clinical lung cancer | 5 | 4 | |